Gene · 338413
Papers2,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
661 to 680 of 2,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. | Cells | 2021 | 34065268 | PubTator, text mining | PubMed |
| Targeting fibroblast growth factor receptors to combat aggressive ependymoma. | Acta Neuropathol | 2021 | 34046693 | PubTator, text mining | PubMed |
| Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. | RSC Med Chem | 2021 | 34041490 | PubTator, text mining | PubMed |
| NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. | J Transl Autoimmun | 2021 | 34041473 | PubTator, text mining | PubMed |
| RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity. | PLoS Biol | 2021 | 34038402 | PubTator, text mining | PubMed |
| Generation of somatic mitochondrial DNA-replaced cells for mitochondrial dysfunction treatment. | Sci Rep | 2021 | 34035362 | PubTator, text mining | PubMed |
| NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway. | Aging (Albany NY) | 2021 | 34030133 | PubTator, text mining | PubMed |
| Relationship Status Update on Astrocytic VEGFR-3 and mTOR Signaling: It's Complicated. | Epilepsy Curr | 2021 | 34025288 | PubTator, text mining | PubMed |
| Gene Expression Changes in a Model Neuron Cell Line Exposed to Autoantibodies from Patients with Traumatic Brain Injury and/or Type 2 Diabetes. | Mol Neurobiol | 2021 | 34013450 | PubTator, text mining | PubMed |
| Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. | Nat Commun | 2021 | 34011995 | PubTator, text mining | PubMed |
| Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1. | Mol Oncol | 2021 | 34003553 | PubTator, text mining | PubMed |
| Balloon cells promote immune system activation in focal cortical dysplasia type 2b. | Neuropathol Appl Neurobiol | 2021 | 34003514 | PubTator, text mining | PubMed |
| Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. | Theranostics | 2021 | 33995674 | PubTator, text mining | PubMed |
| AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? | Front Pharmacol | 2021 | 33995085 | PubTator, text mining | PubMed |
| Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. | Nat Commun | 2021 | 33990561 | PubTator, text mining | PubMed |
| Gαi1 Promoted Proliferation, Migration and Invasion via Activating the Akt-mTOR/Erk-MAPK Signaling Pathway in Renal Cell Carcinoma. | Onco Targets Ther | 2021 | 33976552 | PubTator, text mining | PubMed |
| CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy. | Clin Transl Oncol | 2021 | 33948919 | PubTator, text mining | PubMed |
| Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. | Nat Commun | 2021 | 33947863 | PubTator, text mining | PubMed |
| G protein β5-ATM complexes drive acetaminophen-induced hepatotoxicity. | Redox Biol | 2021 | 33933881 | PubTator, text mining | PubMed |
| Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. | Cancer | 2021 | 33932031 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/papers?page=34